CC
TLOG

Cannell & Co’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Cannell & Co’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-11,713
Closed -$22K – 276
2015
Q3 		$22K Hold
11,713
– – ﹤0.01% 265
2015
Q2 		$27K Buy
+11,713
New +$36.1K ﹤0.01% 269

Other funds holding TLOG

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
FWC
First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

Cannell & Co's TLOG Position: Q4 2015 in Review

Cannell & Co sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q4 2015, closing a stake of 11,713 shares — an estimated $22K sold.

Cannell & Co first reported a position in TLOG in Q2 2015 and held it in 2 quarters. The position peaked at $27K in Q2 2015. 31 funds tracked by Wall St. Rank hold TLOG as of Q4 2015.

  • Cannell & Co reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q4 2015 after selling out during the quarter.
  • Cannell & Co sold 11,713 TetraLogic Pharmaceuticals Corporation shares in Q4 2015, an estimated $22K.
  • Cannell & Co first reported a position in TetraLogic Pharmaceuticals Corporation in Q2 2015 and held it in 2 quarters.
  • Cannell & Co's TetraLogic Pharmaceuticals Corporation position peaked at $27K in Q2 2015.
  • 31 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q4 2015.

Based on Cannell & Co's 13F filing for Q4 2015, filed 11 Feb 2016.